These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation. Rossi S; Motta C; Studer V; Monteleone F; De Chiara V; Buttari F; Barbieri F; Bernardi G; Battistini L; Cutter G; Stüve O; Salvetti M; Centonze D Mult Scler; 2013 Jan; 19(1):59-68. PubMed ID: 22577119 [TBL] [Abstract][Full Text] [Related]
47. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Ehrenreich H; Fischer B; Norra C; Schellenberger F; Stender N; Stiefel M; Sirén AL; Paulus W; Nave KA; Gold R; Bartels C Brain; 2007 Oct; 130(Pt 10):2577-88. PubMed ID: 17728357 [TBL] [Abstract][Full Text] [Related]
48. Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study. Calabrese M; Rocca MA; Atzori M; Mattisi I; Bernardi V; Favaretto A; Barachino L; Romualdi C; Rinaldi L; Perini P; Gallo P; Filippi M Neurology; 2009 Apr; 72(15):1330-6. PubMed ID: 19365054 [TBL] [Abstract][Full Text] [Related]
49. Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis: A Randomized, Controlled Trial. Højsgaard Chow H; Talbot J; Lundell H; Gøbel Madsen C; Marstrand L; Lange T; Mahler MR; Buhelt S; Holm Hansen R; Blinkenberg M; Romme Christensen J; Soelberg Sørensen P; Rode von Essen M; Siebner HR; Sellebjerg F Neurol Neuroimmunol Neuroinflamm; 2021 Sep; 8(5):. PubMed ID: 34429340 [TBL] [Abstract][Full Text] [Related]
50. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Kuhle J; Leppert D; Petzold A; Regeniter A; Schindler C; Mehling M; Anthony DC; Kappos L; Lindberg RL Neurology; 2011 Apr; 76(14):1206-13. PubMed ID: 21346223 [TBL] [Abstract][Full Text] [Related]
51. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Takano R; Misu T; Takahashi T; Sato S; Fujihara K; Itoyama Y Neurology; 2010 Jul; 75(3):208-16. PubMed ID: 20644148 [TBL] [Abstract][Full Text] [Related]
53. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mellergård J; Edström M; Vrethem M; Ernerudh J; Dahle C Mult Scler; 2010 Feb; 16(2):208-17. PubMed ID: 20007431 [TBL] [Abstract][Full Text] [Related]